Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorderas an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically ...
weakness, hypertension, and convulsion. The potential for onset of an event is greatest within the first hour. The majority of cases have occurred within the first 3 hours after injection; however, the event has occurred after 3 hours. Following the 3-hour observation period, healthcare professi...
risperidone(Risperdal),aripiprazole(Abilify) andziprasidone(Geodon). The exact mechanism of action of olanzapine is not known. It may work by blocking receptors for several neurotransmitters (chemicals that nerves use to communicate with each other) in the brain....
risperidone(Risperdal),aripiprazole(Abilify) andziprasidone(Geodon). The exact mechanism of action of olanzapine is not known. It may work by blocking receptors for several neurotransmitters (chemicals that nerves use to communicate with each other) in the brain....
Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorderas an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically ...
Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorderas an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically ...
Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorderas an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically ...
Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorderas an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically ...